The health insurance agency for Mass. state employees will run out of money on Monday
'However, the GIC does not know how soon the Legislature will pass the bill and when the GIC will receive the requested funds, which is why the GIC's health plans are being asked to [delay] payment of members' claims,' Point32Health said.
Get Starting Point
A guide through the most important stories of the morning, delivered Monday through Friday.
Enter Email
Sign Up
Related
:
Advertisement
According to the letter, payments will be delayed until the state approves a budget or until July 1, when the new fiscal year starts and the agency receives more funding.
'It's our hope that this will be resolved really quickly,' said Erika Scibelli, deputy executive director of the GIC. 'We're doing all of our advocacy and working with the legislature and our partners in the administration to advocate to get this moving.'
The funding delays dismayed officials at the Massachusetts Health & Hospital Association. In a statement, the industry group noted that the GIC announced as early as December that it had been over budget every month of the fiscal year. In February, the GIC then publicly stated it was spending approximately $20 million monthly above budgeted amounts.
Advertisement
Expanded use of GLP-1 drugs such as Ozempic are one reason why healthcare spending has surged in Massachusetts.
David J. Phillip/Associated Press
'The GIC apparently does not have any other contingency plan to handle the problem that it has seen developing for at least the past five months,' MHA said in a statement. 'The disruption in GIC claims payments will undoubtedly result in serious financial consequences for the hospitals and health systems that are providing care to the Commonwealth's employees and retirees, and their dependents and survivors that are covered under the GIC umbrella.'
Though it provides insurance benefits to current and retired state employees and their families, the GIC doesn't directly manage its benefits. Instead, it works with four insurers — Point32Health, Mass General Brigham Health Plan, Health New England and Wellpoint — to administer benefits. Providers send bills to the insurers, which then charge the GIC.
The governor had provided roughly level funding in this year's budget for the Group Insurance Commission, said Matthew Murphy, a spokesperson for the Executive Office of Administration and Finance. But the numbers have since proven insufficient.
The agency has struggled in particular with surging prescriptions for pricey weight loss drugs, Scibelli said. Demands for reimbursement increases from providers have also exacerbated spending. Those challenges have pushed premiums higher for GIC members, up between 10.5 percent and 17.1 percent for next year, depending on the plan.
Related
:
The Governor's supplemental budget was expected to fill the gap
through the rest of this fiscal year, allocating $240 million to the GIC through June 30.
Advertisement
But the legislation has stalled on Beacon Hill, where lawmakers were already juggling a series of other bills that created a crush of major spending decisions.
Days after Healey filed her supplemental budget, for example, the House passed a $1.3 billion bill
While the Legislature has had a lot on its plate, the funding delays come at a perilous time for the health care industry, noted Mike Sroczynski, executive vice president and general counsel for the MHA.
'While we appreciate the financial situation of the GIC, this directive is an unacceptable contingency plan to those challenges,' Sroczynski said. 'We implore the GIC to seek an immediate, alternative resolution to its budget deficiency that will not further exacerbate the financial condition of healthcare providers.'
Matt Stout of the Globe Staff contributed reporting
Jonathan Saltzman can be reached at
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
11 hours ago
- New York Post
Average penis size has increased — and Ozempic could be to blame, experts say
Ozempic might shrink waistlines, but it seems to bulge another body part. In a recent Reddit thread, male Ozempic users claimed that the weight-loss drugs helped their penises grow. 'I recently measured myself down there and noticed I gained about one inch,' a person proudly shared on the forum. Advertisement Although there hasn't been enough research done on the correlation between semaglutide and men's genitalia measurements — the average penis size is continuing to rise, and some experts think Ozempic might actually have something to do with it. The average penis has grown nearly 10% from 5.17 inches to 5.63 between 2022 and 2024 in the UK, according to And they're not the only ones seeing this increase. Advertisement The data also revealed that Venezuelan men experienced a massive increase from 1.42 inches to 6.67 inches, within those two years. Dr. Richard Viney, a consultant urological surgeon at the Queen Elizabeth Hospital in Birmingham, thinks Ozempic and similar drugs could be to blame. 'Men's penises shorten as they get older (due to) increasing body fat and increasing prostate size drawing the penis back into the body,' he told Dr. Richard Viney thinks weight-loss drugs, like Ozempic could be to blame for increased penis size. Christopher Sadowski Advertisement 'It is theoretically possible that new drugs like Ozempic and Wegovy, which are used to treat diabetes and obesity, respectively and can cause people to lose weight, could also be a factor. As men lose weight, their penises appear larger.' However, in 2023, research published in the World Journal of Men's Health revealed that the average size of what a guy is packing has grown 24% over nearly 30 years. And that sort of increase has health experts concerned — especially because even two years ago, they couldn't put their finger on what the cause of it is. Advertisement Speculation around weight loss drugs being the culprit is possible — but the Ozempic trend is recent, and this growth for men has clearly been going on for some time now. 'Any overall change in development is concerning, because our reproductive system is one of the most important pieces of human biology,' Dr. Michael Eisenberg, the study's author, told Stanford Medicine's blog Scope. 'If we're seeing this fast of a change, it means that something powerful is happening to our bodies.' Other possible causes could be chemical exposure from pesticides or hygiene products, Eisenberg hypothesized, which can disrupt the hormone-regulating endocrine system. Time will only tell if Ozempic or other lifestyle factors are to blame for well-endowed men.
The Hill
18 hours ago
- The Hill
Beyond MAHA: Defeating obesity requires a new strategy
Obesity is a major health problem facing our country. According to the CDC, more than 40 percent of the U.S. population is obese, defined as having a body-mass index above 30. As astounding at that number is, it is perhaps even more surprising that nearly 20 percent of children in the U.S. are obese. Obesity leads to significant health challenges, including diabetes, stroke, cardiovascular disease and liver disease. It is clear that as a nation we must face this crisis on multiple fronts. Diet and exercise certainly help, and it's critical to ensure that people of all socioeconomic backgrounds have access to healthy foods (free of preservatives, unnecessary dyes, high fructose corn syrups etc.) and are educated in making healthy lifestyle choices. The MAHA or 'Make America Healthy Again' movement has highlighted this as one of its key objectives, and if it is successful, we should see an impact on obesity — especially in children, where diet and exercise have a huge impact on weight-related health outcomes. Obesity in adults, however, is often more challenging. Many adults with obesity struggle to lose weight, despite considerable efforts to modify their lifestyle through diet and exercise. This is because our metabolism changes as we age, and many adults who are overweight develop metabolic dysfunction or 'metabolic syndrome,' which then further perpetuates weight gain and exacerbates the situation. It has become clear in recent years that many people struggling with obesity require medical intervention – not just lifestyle intervention – and that prescriptions can substantially improve weight loss. The explosion in use of GLP-1 agonists, such as Wegovy and Zepbound, over the last two years has underscored the need for medical intervention in obese and overweight patients. Currently, about 6 percent of the U.S. population, or 15 million people, are on GLP-1 weight loss treatments, and the numbers are only expected to increase. However, while most patients lose 10 percent to 25 percent of their body weight while on a GLP-1, they do not maintain GLP-1 treatment in the long-term, with approximately 80 percent of patients discontinuing treatment within 1 year. Gastrointestinal side effects, injectable administration, and high cost have prevented long-term use of GLP-1's for weight maintenance. And unfortunately, most patients gain back all the weight after stopping the medication. Healthcare professionals and the pharmaceutical industry now recognize that obesity — like most other medical conditions — requires an 'arsenal' of treatments, rather than a one-size-fits-all approach. Post-GLP-1 weight maintenance is now widely recognized as an emerging unmet need. And patients who are not candidates for or cannot tolerate GLP-1s require alternatives. Diet and lifestyle modifications are important alongside prescription medications in fighting obesity. If we are going to be successful in overcoming this major health crisis, we need to ensure that both the pharmaceutical industry and groups like MAHA work hand in hand. Both treatment and prevention are critical in order to regain control of our nation's health. Dr. Shoshana Shendelman, Ph.D. is a scientist and entrepreneur who has founded numerous biotech companies. She is a pioneer in the development of drugs and therapeutics for rare and underserved diseases. Currently she is Vice Chair of the Advisory Board of Columbia University Medical Center and Columbia University Vagelos College of Physicians and Surgeons.
Gizmodo
18 hours ago
- Gizmodo
The Ugly Side of Weight-Loss Drugs: Rotten Breath, Damaged Teeth, and Dry Mouth
Ozempic and Wegovy have been hailed as wonder drugs when it comes to weight loss. But as the drug has become more widely used, a number of unintended side-effects have become apparent—with the weight loss drug affecting the appearance of everything from your butt to your feet. 'Ozempic face' is another commonly reported consequences of using these popular weight loss drugs. This is a sunken or hollowed out appearance the face can take on in people taking weight loss drugs. It can also increase signs of ageing—including lines, wrinkles and sagging skin. This happens because semaglutide (the active ingredient in both Ozempic and Wegovy) isn't localised to act just on the fat we want to lose. Instead, it targets all of our body's fat—including in the face. But it isn't just the appearance of your face that semaglutide affects. These drugs may also affect the mouth and teeth, too. And these side-effects could potentially lead to lasting damage. Dry mouth Semaglutide effects the salivary glands in the mouth. It does this by reducing saliva production (hyposalivation), which can in turn lead to dry mouth (xerostomia). This means there isn't enough saliva to keep the mouth wet. It isn't exactly clear why semaglutide has this effect on the salivary glands. But in animal studies of the drug, it appears the drug makes saliva stickier. This means there's less fluid to moisten the mouth, causing it to dry out. GLP-1 receptor agonist drugs (such as semaglutide) can also reduce water intake by affecting areas in the brain responsible for thirst. Low fluid intake further reduces saliva production, and may even cause the saliva to become thick and frothy and the tongue to become sticky. Bad breath One other commonly reported unwanted effect by semaglutide users is bad breath (halitosis). When there's less saliva flowing through the mouth, this encourages bacteria that contribute to bad breath and the formation of cavities to thrive. These bacterial species include Streptococcus mutans and some strains of Lactobacillus. Another species that has been shown to thrive in conditions where saliva is reduced is Porphyromonas gingivalis. This bacteria is a significant contributor to the production of volatile sulphur compounds, which cause the foul odours characteristic of halitosis. Another factor that might explain why semaglutide causes bad breath is because less saliva being produced means the tongue isn't cleaned. This is the same reason why your 'morning breath' is so bad, because we naturally produce less saliva at night. This allows bacteria to grow and produce odours. Case report images show some people taking semaglutide have a 'furry'-like or coated appearance to their tongue. This indicates a build up of bacteria that contribute to bad breath. Tooth damage One of the major side-effects of Ozempic is vomiting. Semaglutide slows how quickly the stomach empties, delaying digestion which can lead to bloating, nausea, and vomiting. Repeated vomiting can damage the teeth. This is because stomach acid, composed primarily of hydrochloric acid, erodes the enamel of the teeth. Where vomiting occurs over a prolonged period of months and years the more damage will occur. The back surface of the teeth (palatal surface) closest to the tongue are more likely to see damage–and this damage may not be obvious to the sufferer. Vomiting also reduces the amount of fluid in the body. When combined with reduced saliva production, this puts the teeth at even greater risk of damage. This is because saliva helps neutralise the acid that causes dental damage. Saliva also contributes to the dental pellicle—a thin, protective layer that the saliva forms on the surface of the teeth. It's thickest on the tongue-facing surface of the bottom row of teeth. In people who produce less saliva, the dental pellicle contains fewer mucins—a type of mucus which helps saliva stick to the teeth. Reducing the risk of damage If you're taking semaglutide, there are many things you can do to keep your mouth healthy. Drinking water regularly during the day can help to keep the oral surfaces from drying out. This helps maintain your natural oral microbiome, which can reduce the risk of an overgrowth of the bacteria that cause bad breath and tooth damage. Drinking plenty of water also enables the body to produce the saliva needed to prevent dry mouth, ideally the recommended daily amount of six to eight glasses. Chewing sugar-free gum is also a sensible option as it helps to encourage saliva production. Swallowing this saliva keeps the valuable fluid within the body. Gums containing eucalyptus may help to prevent halitosis, too. There's some evidence that probiotics may help to alleviate bad breath, at least in the short term. Using a probiotic supplements or consuming probiotic-rich foods (such as yoghurt or kefir) may be a good idea. Practising good basic oral hygiene, tooth brushing, reducing acidic foods and sugary drinks and using a mouthwash all help to protect your teeth as well. Women are twice as likely to have side-effects when taking GLP-1 receptor agonists–including gastrointestinal symptoms such as vomiting. This may be due to the sex hormones oestrogen and progesterone, which can alter the gut's sensitivity. To avoid vomiting, try eating smaller meals since the stomach stays fuller for longer while taking semaglutide. If you are sick, don't immediately brush your teeth as this will spread the stomach's acid over the surface of the teeth and increase the risk of damage. Instead, rinse your mouth out with water or mouthwash to reduce the strength of the acid and wait at least 30 minutes before brushing. It isn't clear how long these side effects last, they'll likely disappear when the medication is stopped, but any damage to the teeth is permanent. Gastrointestinal side-effects can last a few weeks but usually resolve on their own unless a higher dose is taken. Adam Taylor, Professor of Anatomy, Lancaster University. This article is republished from The Conversation under a Creative Commons license. Read the original article.
